Recommendations on the management of coronavirus disease 2019 (COVID-19) were recently released by the National Institutes of Health (NIH) to help guide clinicians caring for patients with COVID-19.
The study authors aimed to assess AE risk and complications of OCS use in patients with asthma since most studies only report them in non-asthmatic patients.
The male patient presented in 2009 with a "3-year history of multiple interconnecting comedones in the axilla and inguinal regions, as well as scarring from previous lesions."
The authors reported that ACQ scores (P=0.04) and oral corticosteroid use (P=0.04) were significantly reduced in high severity completers (n=21) receiving escitalopram.
Severe asthma is a challenging condition. Available therapeutic options for severe asthma include tiotropium, omalizumab, interleukin-5 targeted therapies, macrolide antibiotics, and bronchial thermoplasty.
Results found that infants with an unknown epilepsy etiology, a normal MRI, an EEG displaying hypsarrhythmia, or those already receiving an AED were more likely to be administered ACTH.
Gibson, PG et al. "Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial." DOI: http://dx.doi.org/10.1016/S0140-6736(17)31281-3
Medications can induce HTN through a variety of mechanisms such as volume retention, sympathomimetic activation, and direct vasoconstriction.
The 10-step program assists clinicians in diagnosing and treating CDH.
In addition to clinical presentation, the choice of treatment also depends on patient-related factors, such as age, concomitant co-morbidities, and patient preferences.